Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Study of ZN-c5 in ER+/HER2- Breast Cancer
NCT04176757Phase 1Completed
- Sponsor
- Zeno Alpha, Inc.
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of ZN-c5 in breast cancer, sponsored by Zeno Alpha, Inc. Primary endpoint: Corroborate the single agent Recommended Phase 2 Dose at 15 months. Started Jan 2020; status: completed.
02
Drugs
ZN-c5
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04176757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176757.